

â€l'houcine H Ouafik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4716645/publications.pdf>

Version: 2024-02-01

52
papers

2,084
citations

257450

24
h-index

233421

45
g-index

55
all docs

55
docs citations

55
times ranked

3767
citing authors

#	ARTICLE	IF	CITATIONS
1	PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. International Journal of Radiation Oncology Biology Physics, 2002, 52, 592-598.	0.8	342
2	Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathologica, 2010, 120, 719-729.	7.7	255
3	Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2019, 14, 1095-1101.	1.1	159
4	Differences in steroid 5 α -reductase iso-enzymes expression between normal and pathological human prostate tissue. Journal of Steroid Biochemistry and Molecular Biology, 1999, 68, 189-195.	2.5	122
5	Somatic mosaicism underlies X-linked acrogeria syndrome in sporadic male subjects. Endocrine-Related Cancer, 2016, 23, 221-233.	3.1	75
6	Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer. Cell Metabolism, 2019, 30, 303-318.e6.	16.2	64
7	Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma Malignancy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4865-4872.	3.6	61
8	High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathologica, 2009, 118, 745-754.	7.7	60
9	IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. Journal of Neuro-Oncology, 2011, 105, 591-600.	2.9	59
10	Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution. Annals of Surgical Oncology, 2011, 18, 2937-2945.	1.5	54
11	EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2016, 17, 2132.	4.1	48
12	TRPV2 Mediates Adrenomedullin Stimulation of Prostate and Urothelial Cancer Cell Adhesion, Migration and Invasion. PLoS ONE, 2013, 8, e64885.	2.5	47
13	Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion. Oncotarget, 2017, 8, 15744-15762.	1.8	46
14	Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget, 2015, 6, 11664-11675.	1.8	45
15	Purification, synthesis and characterization of AaCtx, the first chlorotoxin-like peptide from Androctonus australis scorpion venom. Peptides, 2011, 32, 656-663.	2.4	43
16	Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics, 2013, 14, 1047-1051.	1.3	39
17	Droplet digital PCR is a powerful technique to demonstrate frequent <i>FGFR1</i> duplication in dysembryoplastic neuroepithelial tumors. Oncotarget, 2017, 8, 2104-2113.	1.8	39
18	Differential expression of miR200a-3p and miR21 in grade II and grade IV gliomas. Cancer Biology and Therapy, 2014, 15, 938-950.	3.4	37

#	ARTICLE	IF	CITATIONS
19	Differential Expression and Regulation of the Vascular Endothelial Growth Factor Receptors Neuropilin-1 and Neuropilin-2 in Rat Uterus1. <i>Endocrinology</i> , 2001, 142, 613-622.	2.8	36
20	Effect of Serotonin Inhibition on Glucocorticoid and Mineralocorticoid Expression in Various Brain Structures. <i>Neuroendocrinology</i> , 1999, 69, 121-128.	2.5	33
21	Noninvasive near-infrared fluorescent protein-based imaging of tumor progression and metastases in deep organs and intraosseous tissues. <i>Journal of Biomedical Optics</i> , 2014, 19, 016019.	2.6	29
22	Immunocytochemical and in Situ Hybridization Studies of Peptidylglycine Î±-Amidating Monooxygenase in Pituitary Gland*. <i>Endocrinology</i> , 1990, 127, 358-364.	2.8	28
23	Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?. <i>Digestive and Liver Disease</i> , 2011, 43, 917-919.	0.9	24
24	Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the CobasÂ® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. <i>PLoS ONE</i> , 2015, 10, e0120232.	2.5	24
25	Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience. <i>PLoS ONE</i> , 2013, 8, e68945.	2.5	23
26	CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. <i>Blood Advances</i> , 2018, 2, 462-469.	5.2	23
27	Estrogen Regulation of Peptidylglycine Î±-Amidating Monooxygenase Messenger Ribonucleic Acid Levels by a Nuclear Posttranscriptional Event*. <i>Endocrinology</i> , 1997, 138, 5256-5265.	2.8	19
28	Monitoring therapeutic monoclonal antibodies in brain tumor. <i>MAbs</i> , 2014, 6, 1385-1393.	5.2	18
29	Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. <i>European Journal of Cancer</i> , 2011, 47, 1727-1735.	2.8	17
30	CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. <i>Pharmacogenomics</i> , 2012, 13, 393-397.	1.3	17
31	Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 589218.	2.8	17
32	Estrogen Regulation of Peptidylglycine Î±-Amidating Monooxygenase Expression in Anterior Pituitary Gland. <i>Endocrinology</i> , 1997, 138, 379-388.	2.8	15
33	Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study. <i>Oncotarget</i> , 2020, 11, 4648-4654.	1.8	14
34	Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling. <i>Oncotarget</i> , 2015, 6, 7536-7553.	1.8	14
35	Steroids and adrenomedullin growth patterns in human ovarian cancer cells: estrogenic-regulation assay. <i>Gynecologic Oncology</i> , 2003, 91, 651-656.	1.4	13
36	Endo/exo-proteolysis in neoplastic progression and metastasis. <i>Journal of Molecular Medicine</i> , 2005, 83, 856-864.	3.9	12

#	ARTICLE	IF	CITATIONS
37	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer, 2021, 151, 69-75.	2.0	12
38	Lethal toxicity after administration of azacytidine. Pharmacogenetics and Genomics, 2015, 25, 317-321.	1.5	12
39	Effect of hibernation, thyroid hormones and dexamethasone on cytosolic and mitochondrial glycerol-3-phosphate dehydrogenase from jerboa (Jaculus orientalis). Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2000, 125, 439-449.	1.6	11
40	Prognostic significance of tumor-related proteases as a function of the estrogen receptor status. Cancer Biology and Therapy, 2011, 11, 277-283.	3.4	10
41	Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 94-107.	1.1	9
42	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. JTO Clinical and Research Reports, 2020, 1, 100052.	1.1	9
43	Identification of the chemical composition of six essential oils with mass spectroscopy and evaluation of their antibacterial and antioxidant potential. Flavour and Fragrance Journal, 2021, 36, 465-476.	2.6	9
44	Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics, 2019, 20, 931-938.	1.3	8
45	Identification of a Novel cis-Element in the 3'-Untranslated Region of Mammalian Peptidylglycine \pm -Amidating Monooxygenase Messenger Ribonucleic Acid. Endocrinology, 1998, 139, 894-904.	2.8	7
46	Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. European Journal of Clinical Pharmacology, 2010, 66, 959-960.	1.9	7
47	Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2018, 56, 748-753.	2.3	6
48	Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant. Pharmacogenetics and Genomics, 2014, 24, 527-529.	1.5	4
49	Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study. PLoS ONE, 2020, 15, e0234387.	2.5	3
50	Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1083-1088.	2.5	2
51	Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors. Frontiers in Oncology, 2021, 11, 753244.	2.8	2
52	\pm 1-Adrenergic regulation of peptidylglycine \pm -amidating monooxygenase gene expression in cultured rat cardiac myocytes: transcriptional studies and messenger ribonucleic acid stability. Molecular and Cellular Endocrinology, 1999, 154, 89-100.	3.2	1